Evidence map›Paper›PMID 23337555›Full record

ArticleOphthalmology2013

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Stephanie A Hagstrom, Gui-Shuang Ying, Gayle J T Pauer, Gwen M Sturgill-Short, Jiayan Huang, David G Callanan, Ivana K Kim, Michael L Klein, Maureen G Maguire, Daniel F Martin and 1 more

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00593450 (Comparison of Age-related Macular Degeneration Treatments Trials), which is not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 4 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00593450 phase3completednot on this map

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)

TypeinterventionalSponsorUniversity of PennsylvaniaRan2008 to 2015Enrolled1,208ConditionsAge Related Macular DegenerationArmsranibizumab, bevacizumab
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Stephanie A HagstromCole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. Electronic address: hagstrs@ccf.org.
Gui-Shuang YingDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Gayle J T PauerCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Gwen M Sturgill-ShortCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Jiayan HuangDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
David G CallananTexas Retina Associates, Arlington, Texas.
Ivana K KimRetina Service, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Michael L KleinCasey Eye Institute, Oregon Health Sciences Center, Portland, Oregon.
Maureen G MaguireDepartment of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania.
Daniel F MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Comparison of AMD Treatments Trials Research Group
University of Pennsylvania · USCleveland Clinic · USCase Western Reserve University · USCleveland Eye Clinic · USHarvard University · USTexas Retina Associates (United States) · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Coordinating Center for the Comparison of AMD Treatments TrialsU10EY017823 · NEI · UNIVERSITY OF PENNSYLVANIA · PI MAGUIRE, MAUREEN G · 2006 to 2012
$19.2M
Photograph Reading Center for the Comparison of AMD Treatment TrialsU10EY017826 · NEI · UNIVERSITY OF PENNSYLVANIA · PI GRUNWALD, JUAN E · 2006 to 2013
$2.8M
Comparison of AMD Treatment Trials-OCT Reading CenterU10EY017825 · NEI · DUKE UNIVERSITY · PI JAFFE, GLENN · 2006 to 2013
$2.3M
Chair Grant for the Comparison of AMD Treatment TrialsU10EY017828 · NEI · EMORY UNIVERSITY · PI MARTIN, DANIEL F · 2006 to 2012
$1.9M
NCATS NIH HHS UL1 TR000439NEI NIH HHS U10 EY017823NEI NIH HHS U10 EY017825NEI NIH HHS U10 EY017826NEI NIH HHS U10 EY017828
6 · The paper itself

Abstract

purposeTo evaluate the pharmacogenetic relationship between genotypes of single nucleotide polymorphisms (SNPs) known to be associated with age-related macular degeneration (AMD) and response to treatment with ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech) for neovascular AMD.

designClinical trial.

participantsEight hundred thirty-four (73%) of 1149 patients participating in the Comparison of AMD Treatments Trials (CATT) were recruited through 43 CATT clinical centers.

methodsEach patient was genotyped for SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3), using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA). MAIN OUTCOMES MEASURES: Genotypic frequencies were compared with clinical measures of response to therapy at one year, including mean visual acuity (VA), mean change in VA, 15-letter or more increase in VA, retinal thickness, mean change in total foveal thickness, presence of fluid on OCT, presence of leakage on fluorescein angiography (FA), mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. To adjust for multiple comparisons, P≤0.01 was considered statistically significant.

resultsNo statistically significant differences in response by genotype were identified for any of the clinical measures studied. Specifically, there were no high-risk alleles that predicted final VA or change in VA, the degree of anatomic response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size), or the number of injections. Furthermore, a stepwise analysis failed to show a significant epistatic interaction among the variants analyzed; that is, response did not vary by the number of risk alleles present. The lack of association was similar whether patients were treated with ranibizumab or bevacizumab or whether they received monthly or pro re nata dosing.

conclusionsAlthough specific alleles for CFH, ARMS2, HTRA1, and C3 may predict the development of AMD, they did not predict response to anti-vascular endothelial growth factor therapy.

Indexed as

Polymorphism, Single NucleotideAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabComplement C3Complement Factor HFemaleFluorescein AngiographyGene FrequencyGenotypeHigh-Temperature Requirement A Serine Peptidase 1HumansMacular DegenerationMaleAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedARMS2 protein, humanBevacizumabCFH protein, humanComplement C3Complement Factor HHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanProteinsRanibizumabSerine EndopeptidasesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID23337555
PMCPMC3633658
OpenAlexW2162946426

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.